HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Lineage Cell Therapeutics (AMEX:LCTX) and maintains a price target of $9 for the stock. No additional financial figures or strategic changes were mentioned in the article.